SK-BR-3

SK-BR-3是在1970年由纪念斯隆-凯特琳癌症中心的科研人员分离的人类乳癌细胞系，目前应用于乳癌治疗方案的研究，尤其是在靶向HER2/neu的研究^[1]。

特征

SK-BR-3细胞与AU565细胞分离自同一名曾接受过放射及5-氟尿嘧啶等治疗的患者^[2]。SK-BR-3细胞源自于一名43岁白人女性患者体内，由乳癌引起的胸腔积液^[1]，并且过度表达着HER2/neu产物，而该产物被认为与多种乳癌增殖的途径有关。SK-BR-3细胞已知会以葡萄状簇（grape-like clusters）的形式生长，其侵袭性表型与体内细胞类似^[3]。

科研用途

SK-BR-3细胞已用于寻求能克服曲妥珠单抗对乳腺癌（过度表达人类表皮生长因子受体2）的抵抗力的研究^[4]。而且有科研人员已经检查了该细胞系在CRISPR/Cas9基因编辑与转染中的抗体抗性^[5]，以及在微环境存在波动的情况下，基于HER2/neu的癌症治疗中的应用^[6]。

参考资料

^ ^1.0 ^1.1 SK-BR-3: Human Breast Cancer Cell Line (ATCC HTB-30). Memorial Sloan-Kettering Cancer Center. [2018-06-18]. （原始内容存档于2018-06-18）.
^ SK-BR-3 cells. Addex Bio. [2018-06-18]. （原始内容存档于2018-06-19）.
^ Holliday, DL; Speirs, V. Choosing the right cell line for breast cancer research.. Breast cancer research : BCR. 2011-08-12, 13 (4): 215 [2020-01-05]. PMID 21884641. doi:10.1186/bcr2889. ^{[永久失效链接]}
^ Tseng, PH; Wang, YC; Weng, SC; Weng, JR; Chen, CS; Brueggemeier, RW; Shapiro, CL; Chen, CY; Dunn, SE; Pollak, M; Chen, CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.. Molecular pharmacology. 2006-11, 70 (5): 1534–41 [2020-01-05]. PMID 16887935. doi:10.1124/mol.106.023911. ^{[永久失效链接]}
^ Cao, J; Wu, L; Zhang, SM; Lu, M; Cheung, WK; Cai, W; Gale, M; Xu, Q; Yan, Q. An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting.. Nucleic acids research. 2016-11-02, 44 (19): e149 [2020-01-05]. PMID 27458201. doi:10.1093/nar/gkw660. ^{[永久失效链接]}
^ Weigelt, B; Lo, AT; Park, CC; Gray, JW; Bissell, MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.. Breast cancer research and treatment. 2010-07, 122 (1): 35–43 [2020-01-05]. PMID 19701706. doi:10.1007/s10549-009-0502-2. ^{[永久失效链接]}

外部链接

Cellosaurus entry for SK-BR-3（页面存档备份，存于互联网档案馆）

[MSKCC-1] 1.0 ^1.1 SK-BR-3: Human Breast Cancer Cell Line (ATCC HTB-30). Memorial Sloan-Kettering Cancer Center. [2018-06-18]. （原始内容存档于2018-06-18）.

[2] SK-BR-3 cells. Addex Bio. [2018-06-18]. （原始内容存档于2018-06-19）.

[3] Holliday, DL; Speirs, V. Choosing the right cell line for breast cancer research.. Breast cancer research : BCR. 2011-08-12, 13 (4): 215 [2020-01-05]. PMID 21884641. doi:10.1186/bcr2889. ^{[永久失效链接]}

[4] Tseng, PH; Wang, YC; Weng, SC; Weng, JR; Chen, CS; Brueggemeier, RW; Shapiro, CL; Chen, CY; Dunn, SE; Pollak, M; Chen, CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.. Molecular pharmacology. 2006-11, 70 (5): 1534–41 [2020-01-05]. PMID 16887935. doi:10.1124/mol.106.023911. ^{[永久失效链接]}

[5] Cao, J; Wu, L; Zhang, SM; Lu, M; Cheung, WK; Cai, W; Gale, M; Xu, Q; Yan, Q. An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting.. Nucleic acids research. 2016-11-02, 44 (19): e149 [2020-01-05]. PMID 27458201. doi:10.1093/nar/gkw660. ^{[永久失效链接]}

[6] Weigelt, B; Lo, AT; Park, CC; Gray, JW; Bissell, MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.. Breast cancer research and treatment. 2010-07, 122 (1): 35–43 [2020-01-05]. PMID 19701706. doi:10.1007/s10549-009-0502-2. ^{[永久失效链接]}

[1]

[2]

[3]

[4]

[5]

[6]